SystImmune Inc.

7 clinical trials · Sponsor

Record	Firm	Date
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) (NCT07625644)	SystImmune Inc.	2026-06-01
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors (NCT07080242)	SystImmune Inc.	2025-04-28
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors (NCT06714617)	SystImmune Inc.	2025-04-10
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 (NCT06714591)	SystImmune Inc.	2024-12-19
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors (NCT06293898)	SystImmune Inc.	2024-02-09
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors (NCT05983432)	SystImmune Inc.	2023-08-08

Every clearance here is in the API, with alerts when new ones post.